Works matching IS 01676997 AND DT 2021 AND VI 39 AND IP 6

Results: 30
    1
    2

    Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1641, doi. 10.1007/s10637-021-01152-z
    By:
    • Marret, Grégoire;
    • Isambert, Nicolas;
    • Rezai, Keyvan;
    • Gal, Jocelyn;
    • Saada-Bouzid, Esma;
    • Rolland, Frédéric;
    • Chausson, Maggy;
    • Borcoman, Edith;
    • Alt, Marie;
    • Klijanienko, Jerzy;
    • Vansteene, Damien;
    • Guigay, Joël;
    • Kamal, Maud;
    • Bièche, Ivan;
    • Le Tourneau, Christophe
    Publication type:
    Article
    3
    4
    5
    6
    7

    Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1598, doi. 10.1007/s10637-021-01147-w
    By:
    • Kaneda, Hiroyasu;
    • Sawa, Kenji;
    • Daga, Haruko;
    • Okada, Asuka;
    • Nakatani, Yuki;
    • Atagi, Shinji;
    • Okishio, Kyoichi;
    • Tani, Yoko;
    • Matsumoto, Yoshiya;
    • Ogawa, Koichi;
    • Nakahama, Kenji;
    • Izumi, Motohiro;
    • Mitsuoka, Shigeki;
    • Kawaguchi, Tomoya
    Publication type:
    Article
    8
    9
    10
    11

    Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1587, doi. 10.1007/s10637-021-01141-2
    By:
    • Italiano, Antoine;
    • Miller Jr, Wilson H.;
    • Blay, Jean-Yves;
    • Gietema, Jourik A.;
    • Bang, Yung-Jue;
    • Mileshkin, Linda R.;
    • Hirte, Hal W.;
    • Higgins, Brian;
    • Blotner, Steven;
    • Nichols, Gwen L.;
    • Chen, Lin Chi;
    • Petry, Claire;
    • Yang, Qi Joy;
    • Schmitt, Christophe;
    • Jamois, Candice;
    • Siu, Lillian L.
    Publication type:
    Article
    12

    Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1732, doi. 10.1007/s10637-021-01140-3
    By:
    • Miyawaki, Taichi;
    • Kenmotsu, Hirotsugu;
    • Yabe, Michitoshi;
    • Kodama, Hiroaki;
    • Nishioka, Naoya;
    • Miyawaki, Eriko;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Wakuda, Kazushige;
    • Ono, Akira;
    • Deguchi, Shoichi;
    • Mitsuya, Koichi;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Mori, Keita;
    • Harada, Hideyuki;
    • Hayashi, Nakamasa;
    • Takahashi, Kazuhisa;
    • Takahashi, Toshiaki
    Publication type:
    Article
    13
    14

    Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1577, doi. 10.1007/s10637-021-01138-x
    By:
    • Kummar, Shivaani;
    • Srivastava, Apurva K.;
    • Navas, Tony;
    • Cecchi, Fabiola;
    • Lee, Young H.;
    • Bottaro, Donald P.;
    • Park, Sook Ryun;
    • Do, Khanh T.;
    • Jeong, Woondong;
    • Johnson, Barry C.;
    • Voth, Andrea R.;
    • Rubinstein, Larry;
    • Wright, John J.;
    • Parchment, Ralph E.;
    • Doroshow, James H.;
    • Chen, Alice P.
    Publication type:
    Article
    15
    16

    Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1716, doi. 10.1007/s10637-021-01136-z
    By:
    • Takinami, Masaki;
    • Ono, Akira;
    • Kawabata, Takanori;
    • Mamesaya, Nobuaki;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Wakuda, Kazushige;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Endo, Masahiro;
    • Kiyohara, Yoshio;
    • Yasui, Hirofumi;
    • Niwakawa, Masashi;
    • Takahashi, Toshiaki
    Publication type:
    Article
    17
    18

    Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1656, doi. 10.1007/s10637-021-01134-1
    By:
    • Ashkar, Ryan;
    • Feldman, Darren R.;
    • Adra, Nabil;
    • Zaid, Mohammad Abu;
    • Funt, Samuel A.;
    • Althouse, Sandra K.;
    • Perkins, Susan M.;
    • Snow, Christin I.;
    • Lazzara, Kayla M.;
    • Sego, Lina M.;
    • Quinn, David I.;
    • Hanna, Nasser H.;
    • Einhorn, Lawrence H.;
    • Albany, Costantine
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26

    Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 6, p. 1649, doi. 10.1007/s10637-021-01125-2
    By:
    • Kotani, Daisuke;
    • Yoshino, Takayuki;
    • Kotaka, Masahito;
    • Kawazoe, Akihito;
    • Masuishi, Toshiki;
    • Taniguchi, Hiroya;
    • Yamazaki, Kentaro;
    • Yamanaka, Takeharu;
    • Oki, Eiji;
    • Muro, Kei;
    • Komatsu, Yoshito;
    • Bando, Hideaki;
    • Satake, Hironaga;
    • Kato, Takeshi;
    • Tsuji, Akihito
    Publication type:
    Article
    27
    28
    29
    30